(RTTNews) - Biopharmaceutical company Entrada Therapeutics, Inc. (TRDA) announced Wednesday the completion of dosing for the first and second cohorts of its Phase 1 clinical trial, ENTR-601-44-101.
Entrada plans to announce data from ENTR-601-44-101 in the second half of 2024.
The primary objective of Entrada's double-blind, single ascending dose Phase 1 clinical trial, which is expected to enroll approximately 40 participants, is to evaluate the safety and tolerability of a single dose of ENTR-601-44 in healthy male volunteers.
ENTR-601-44-101 will also evaluate pharmacokinetics and target engagement, as measured by exon skipping in the skeletal muscle.
Entrada was previously notified by the FDA that the IND for the Phase 1 clinical trial of ENTR-601-44 had been placed on clinical hold.
Despite providing additional information to the FDA, the Company was informed that the Agency declined to lift the clinical hold.
